4.8 Editorial Material

Global Impact of 2017 American Heart Association/American College of Cardiology Hypertension Guidelines A Perspective From Japan

Journal

CIRCULATION
Volume 137, Issue 6, Pages 543-545

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.117.032851

Keywords

blood pressure monitoring; ambulatory; Japan

Funding

  1. Teijin Pharma, Ltd
  2. Omron Healthcare Co, Ltd
  3. Fukuda Denshi
  4. Bayer Yakuhin, Ltd
  5. AD Co, Ltd
  6. Daiichi Sankyo Co, Ltd
  7. Mochida Pharmaceutical Co, Ltd
  8. EA Pharma
  9. Boehringer Ingelheim Japan Inc
  10. Tanabe Mitsubishi Pharma Corp
  11. Shionogi Co, Ltd
  12. MSD KK
  13. Sanwa Kagaku Kenkyusho Co, Ltd
  14. Bristol-Myers Squibb KK
  15. Grants-in-Aid for Scientific Research [26293192] Funding Source: KAKEN

Ask authors/readers for more resources

The 2017 American Heart Association/American College of Cardiology (AHA/ACC) guidelines for the prevention, detection, evaluation, and management of high blood pressure (BP) in adults were recently released. 1 The core concept in these guidelines is earlier and tighter BP control over 24 hours, with the aim of providing more sustained target organ protection and cardiovascular disease prevention. These guidelines lower the threshold of hypertension diagnosis and target BP levels to 130/80 mm Hg. This direction of strict BP control with a new definition and universal target goal for hypertension will be the topic of debate among the guideline developing committee members of the Japanese Society of Hypertension.(2)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available